Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial
Background: DLBS3233, recognized as an agent enhancing insulin sensitivity, has exhibited promise as a therapeutic option for addressing type 2 diabetes mellitus (T2DM). This study aimed to evaluate the effectiveness and safety of DLBS3233, a natural compound, in individuals newly diagnosed with T2D...
Saved in:
Main Authors: | Heri Nugroho (Author), Nurmilawati Nurmilawati (Author), Diana Novitasari (Author), Lidia Rombeallo (Author), Rambu Farah Effendi (Author), Reski Reski (Author), Intan Surayya (Author), Nugroho Agung Daryanto (Author), Solomon Putera (Author), Raymond Rubianto Tjandrawinata (Author) |
---|---|
Format: | Book |
Published: |
Interna Publishing,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insulin sensitizer in prediabetes: a clinical study with DLBS3233, a combined bioactive fraction of Cinnamomum burmanii and Lagerstroemia speciosa
by: Manaf A, et al.
Published: (2016) -
The Effect and Safety Assessment of Metformin and DLBS3233 (A Bioactive Fraction of Lagerstroemia speciosa and Cinnamomum burmannii) on Improving Metabolic Parameters in Women with Polycystic Ovary Syndrome
by: Hidayat ST, et al.
Published: (2023) -
Potential Antiaging Effects of DLBS1649, a Centella asiatica Bioactive Extract
by: Karsono AH, et al.
Published: (2021) -
Gastroprotective Effect of DLBS2411 Bioactive Fraction from Cinnamomum burmannii Against Ethanol-Induced Gastric Damage in Rats
by: Tjandrawinata RR, et al.
Published: (2020) -
A Clinical Trial on Biological Half Life of Bioactive Protein from Lumbricus rubellus, DLBS1033 in Healthy Volunteers
by: Anggi Gayatri, et al.
Published: (2018)